Philippe Wiesel
Chief Tech/Sci/R&D Officer at Calliditas Therapeutics Suisse SA
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Claudio Nessi | M | 56 |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.
University of Lausanne
| 5 years |
| Elias Papatheodorou | M | 55 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 9 years |
| Alexandre Grassin | M | 46 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 12 years |
| Guy Mustaki | M | 64 |
University of Lausanne
| 33 years |
| Jesús Martin-Garcia | M | 62 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alexandre Col | M | 61 |
University of Lausanne
| 10 years |
| Bertrand Ducrey | M | - |
University of Lausanne
| 4 years |
| Jacques Herve | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Christophe Reymond | M | - |
University of Lausanne
| 9 years |
| Kathia Blauth | F | 52 |
University of Lausanne
| 4 years |
| Beat Stocker | M | - |
University of Lausanne
| 2 years |
| Isabelle Romy | M | 59 |
University of Lausanne
| 3 years |
| Eric Meldrum | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Liang Qiao | M | 62 |
University of Lausanne
| 3 years |
| Thomas Paulsen | M | 59 |
University of Lausanne
| 3 years |
| Ziping Liu | M | - |
University of Lausanne
| 3 years |
| Jeanette Wood | M | 72 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 2 years |
| José François Sierdo | M | 61 |
University of Lausanne
| 4 years |
| Oliver M. Bartholet | M | 58 |
University of Lausanne
| 3 years |
| Rongqiang Liu | M | 58 |
University of Lausanne
| 3 years |
| Stéphane Pittet | M | 51 |
University of Lausanne
| 2 years |
| Bertrand Sager | M | 58 |
University of Lausanne
| 3 years |
| Bernard Guillelmon | M | 57 |
University of Lausanne
| 1 years |
| Werner J. Bauer | M | 73 |
University of Lausanne
| - |
| Gilles Robert-Nicoud | M | 54 |
University of Lausanne
| 3 years |
| Anouck Ansermoz | F | - |
University of Lausanne
| 3 years |
| Roger H. Hartmann | M | 66 |
University of Lausanne
| 5 years |
| Laura Foresti | F | - |
University of Lausanne
| 3 years |
| Daniel Crausaz | M | 67 |
University of Lausanne
| 2 years |
| Jessie Agostinelli | F | 50 |
University of Lausanne
| 4 years |
| Yuan Wei Chen | M | 61 |
University of Lausanne
| 4 years |
| Thomas Steinmann | M | 63 |
University of Lausanne
| 3 years |
| Joseph McCracken | M | 71 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Gilles Nobécourt | M | 67 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Ernest Loumaye | M | 71 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 5 years |
| Christian Meixenberger | M | 64 |
University of Lausanne
| 2 years |
| Stéphane Verdood | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Rajna Gibson Brandon | M | 61 |
University of Lausanne
| 9 years |
| Bérangère Ruchat | M | 54 |
University of Lausanne
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 39 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philippe Wiesel
- Personal Network